Another study reported that treatment with a humanized anti-IL-5 monoclonal antibody called mepolizumab (MEP) can attenuate allergen-induced Th2 inflammation and tissue remodeling by downregulating Chi3l1 levels in asthma patients [295]. This evidence concerns the gene IL5 and asthma.